InvestSMART

Algorae Pharmaceuticals Limited (ASX: 1AI) - Share Price

Current share price for 1AI : $0.009 0.001 (5.26%)+

Algorae Pharmaceuticals Limited is a pharmaceutical development company with three drug candidates and a proprietary artificial intelligence (AI) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It biopharmaceutical prediction platform under development. The therapeutic pipeline comprises AI-116 for dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson disease.

1AI General Information +

ASX Code 1AI
Website http://www.algoraepharma.com
Industry/Sector Biotechnology
Market Cap ($M) 18
1AI Share Price $0.009
Day High $0.010
Day Low $0.009
Last Close $0.010
1AI Share Price Movement $0.00 ( 5.26% )
Prices as at 16:40, 26 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Algorae Pharmaceuticals Limited (1AI) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Algorae Pharmaceuticals Limited (1AI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Algorae Pharmaceuticals Limited (1AI) price-sensitive announcements

1AI - Algorae executes Licence & Supply Agreement with Umedica
Algorae Pharmaceuticals announced that its wholly owned subsidiary, AlgoraeRx Pty Ltd, has
Algorae Pharmaceuticals Limited (1AI)
19 Oct 2026 | 9:00 AM
1AI - Peter Mac partners with Algorae on 3rd AI validation program
Algorae Pharmaceuticals Limited (ASX: 1AI) announced that it has entered into an agreement
Algorae Pharmaceuticals Limited (1AI)
16 Oct 2026 | 9:00 AM
1AI - Appendix 4E and 2026 Annual Report
Algorae Pharmaceuticals Limited’s Appendix 4E and 2026 Annual Report for the financial yea
Algorae Pharmaceuticals Limited (1AI)
31 Aug 2026 | 4:02 PM
1AI - Quarterly Activities Report/Appendix 4C Cashflow Statement
In the June 2026 Quarterly Activities Report, Algorae Pharmaceuticals Limited reported pro
Algorae Pharmaceuticals Limited (1AI)
31 Jul 2026 | 9:14 AM

Algorae Pharmaceuticals Limited (1AI) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Algorae executes Licence & Supply Agreement with Umedica 19 Oct 2026 9:00AM $0.009 $0.009 fallen by 0%
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Peter Mac partners with Algorae on 3rd AI validation program 16 Oct 2026 9:00AM $0.009 $0.009 fallen by 0%
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Notice of Annual General Meeting/Proxy Form 7 Oct 2026 4:46PM $0.009 $0.009 fallen by 0%
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Change of Director's Interest Notice - DH 30 Sep 2026 5:03PM $0.009 $0.009 fallen by 0%
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Date of AGM and Closing Date for Director Nominations 10 Sep 2026 8:22AM $0.010 $0.009 fallen by 10%
Algorae Pharmaceuticals Limited (1AI)
ORDINARY FULLY PAID
Health Care $18 Notification of cessation of securities - 1AI 2 Sep 2026 5:19PM $0.011 $0.009 fallen by 18.18%

1AI Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$2.71 -$0.20 200.00% 0.00 0.00 0.00% 0.0%
2025A -$0.80 -$0.10 -61.50% 0.00 0.00 0.00% 0.0%
2024A -$2.10 -$0.10 -18.80% 0.00 0.00 0.00% 0.0%

1AI Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Algorae Pharmaceuticals Limited (1AI) $20M 2.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $94,125M 0.7309 -0.4392 0.0602 12.1513 21.6669 20.4370 2.17% 2.17% 2.24%
Mesoblast Limited (MSB) $2,381M -0.4501 0.0000 0.0000 0.0000 0.0000 831.8182 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,781M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,649M -1.3893 0.0000 -0.5235 0.0000 160.7059 337.2840 0.00% 0.00% 0.00%

1AI Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.52 0.00
Market 0.30 13.30 1.03 0.72
Sector 0.78 41.90 2.29 2.12

1AI Directors

Name Position Start Date
Mr David Richard Hainsworth Executive Chairman, Executive Director, Interim CEO 30 Oct 2022
Mr Troy Robert Valentine Non-Executive Director 14 Jul 2026
Mr David Gulland Non-Executive Director 10 Mar 2026

Algorae Pharmaceuticals Limited (1AI) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
5 Mar 2026 HAINSWORTH, David Buy Indirect Shares 312,500 $0.012 $3,750.000
5 Mar 2026 HAINSWORTH, David Exercise Options 312,500 $0.012 $3,750.000
22 Dec 2025 HAINSWORTH, David Issued Options 5,125,000 $0.001 $5,125.000

See all changes in directors' interest & trades for Algorae Pharmaceuticals Limited (1AI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

1AI Management

Name Position
Vishal Shah Chief Commercial Officer
Catherine Earlie Joint Company Secretary
Geraldine Holland Joint Company Secretary

1AI Calendar of Events

Date Event
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)
26 February 2027 Report (Interim)
05 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.